Sort
48,018 grants matching “immunotherapy”
Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms
$605,142Sunil S. Badve · Emory University · R01 · FY2025 · CA
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
$605,116Isabelle Caroline Le Poole · Northwestern University At Chicago · R01 · FY2023 · HL
TISSUE-ENGINEERED CANCER METASTASIS TO IMPROVE THE ABSCOPAL EFFECT AND CANCER IMMUNOTHERAPY IN MELANOMA
$605,018University Of North Carolina At Chapel Hill · · FY2016 · Department of the Army
PFI-TT: Immuno-Dx: A Biomedical Platform Technology for Personalized Diagnostics
$605,000Umer Hassan · Rutgers University New Brunswick · · FY2023 · TIP
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
$604,997Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · NS
Immune Exclusion in Cancer Immunotherapy
$604,941Riyue Bao · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DE
Immune Exclusion in Cancer Immunotherapy
$604,941Riyue Bao · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · DE
Immune Exclusion in Cancer Immunotherapy
$604,941Riyue Bao · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DE
Immune manipulation to generate tumor immunity and regulate GVHD after allogeneic HCT
$604,938Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2023 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES
$604,916University Of Wisconsin Madison · U10 · FY2002 · CA
GENOMIC AND IMMUNOLOGIC CORRELATES OF IMMUNOTHERAPY RESPONSE AND RESISTANCE VIA LONGITUDINAL TUMOR AND EXTRACELLULAR VESICLE (EV) ANALYSIS
$604,800The General Hospital Corporation · · FY2019 · Department of the Army
TrialNet: Diabetes Type 1 Prevention
$604,774Peter A Gottlieb · University Of Colorado Denver · U01 · FY2014 · DK
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
$604,694David M. Lewinsohn · Oregon Health & Science University · R01 · FY2020 · AI
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
$604,693Deric L Wheeler · University Of Wisconsin-Madison · R01 · FY2025 · CA
Deconvoluting CAR T cell heterogeneity to engineer durable antitumor protection
$604,627Yina Hsing Huang · Dartmouth College · R01 · FY2025 · CA
Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge
$604,528Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2020 · AI
Immunobiology and immunotherapy of pancreatic cancer
$604,414Robert H Vonderheide · University Of Pennsylvania · R01 · FY2014 · CA
Regulators of Cancer Immunotherapy Response
$604,374Myles A Brown · Dana-Farber Cancer Inst · R01 · FY2021 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
$604,372University Of Wisconsin Madison · U10 · FY2005 · CA
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma
$604,335John Tanner Wilson · Vanderbilt University · R01 · FY2022 · CA
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
$604,257Donald Ym Leung · National Jewish Health · U01 · FY2021 · AR
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer
$604,219Arvin Dar · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
$604,169University Of Wisconsin Madison · U10 · FY2004 · CA
Epigenetic and immunologic aspects of high-grade neuroendocrine cancers
$604,110Nitin Roper · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma
$604,097Arash Ash Alizadeh · Stanford University · U01 · FY2019 · CA